Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis Tavs Qvist,

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations Emilie Catherinot, Anne-Laure Roux, Marie-Anne.

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa.

Intravenous antibiotics given for 2 weeks do not eradicate persistent Staphylococcus aureus clones in cystic fibrosis patients C. Andersen, B.C. Kahl,

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Infections in Patients with Cystic Fibrosis

Megan W. France, Mary E. Dodd, John R. Govan, Catherine J. Doherty, A

Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response Helle Krogh Johansen, Kasper.

Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment Winnie Ridderberg, Karen E.M.

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Journal of Cystic Fibrosis

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

Increasing nontuberculous mycobacteria infection in cystic fibrosis

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination M.-R. Lee,

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

The Journal of Cystic Fibrosis: Sunny perspectives

Vitamin A and lung function in CF

Charles R. Esther, Denise A

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Physiologic endpoints for clinical studies for cystic fibrosis

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Chee Y. Ooi, Peter R. Durie Journal of Cystic Fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

Lung clearance index during hospital admission in school-age children with cystic fibrosis Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai,

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study Dr David C.

Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case– control study Maarten Verregghen, Harry G. Heijerman, Monique.

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Robert P. Thomen, Laura L. Walkup, David J. Roach, Zackary I

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Segregation—the perspectives of young patients and their parents

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis Tavs Qvist, David Taylor-Robinson, Elisabeth Waldmann, Hanne Vebert Olesen, Christine Rønne Hansen, Inger Hee Mathiesen, Niels Høiby, Terese L. Katzenstein, Rosalind L. Smyth, Peter J. Diggle, Tania Pressler Journal of Cystic Fibrosis Volume 15, Issue 3, Pages 380-385 (May 2016) DOI: 10.1016/j.jcf.2015.09.007 Copyright © 2015 The Authors Terms and Conditions

Journal of Cystic Fibrosis 2016 15, 380-385DOI: (10. 1016/j. jcf. 2015 Copyright © 2015 The Authors Terms and Conditions

Fig. 1 Change in the rate of decline of lung function (%FEV1) following onset of each infection and clearance of nontuberculous mycobacterial infection. The point sizes are drawn proportional to the precision of the estimates. Journal of Cystic Fibrosis 2016 15, 380-385DOI: (10.1016/j.jcf.2015.09.007) Copyright © 2015 The Authors Terms and Conditions

Fig. 2 Effect on lung function of chronic infection from onset to end stage lung disease in Danish cystic fibrosis patients. The figure visualizes the impact of onset of chronic infections by plotting population averaged %FEV1 trajectories before and after onset of infection with other model parameters held constant. Thus for a patient born in 1994 and infected at age 20, all other things being equal, end stage lung disease will occur after 13.6, 14.7, 16.8, 21.3, 24.4 and 35.6years for MABSC, B. cepacia complex, A. xylosoxidans, P. aeruginosa, S. maltophilia and MAC respectively. Footnote: Trajectories plotted and held constant for a person born in the 1994–2004 birth cohort, mutually adjusted for other co-variates in the model, with onset of infection occurring at age 20. Journal of Cystic Fibrosis 2016 15, 380-385DOI: (10.1016/j.jcf.2015.09.007) Copyright © 2015 The Authors Terms and Conditions

Fig. 3 Mean effect on lung function of Mycobacterium abscessus complex infection from onset and clearance of the infection in Danish patients with CF. Footnote: Trajectories plotted and held constant for a person born in the 1994–2004 birth cohorts, mutually adjusted for other co-variates in the model, and extended beyond the range of the observed data to demonstrate progression to end stage lung disease. Journal of Cystic Fibrosis 2016 15, 380-385DOI: (10.1016/j.jcf.2015.09.007) Copyright © 2015 The Authors Terms and Conditions